glycoprotein phospholipase D

; acts to liberate anchored alkaline phosphatase

Also Known As:

GPI-PLD; PI-glycan phospholipase D; PI-glycan-PLD; PIPLD; PtdIns-GS-phospholipase D; alkaline phosphatase anchor hydrolase; glycosylphosphatidylinositol-specific phospholipase D; phosphatidylinositol-glycan phospholipase D; phosphoinositol-specific phospholipase D

Networked: 43 relevant articles (1 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Esterases: 1574
      - Phosphoric Diester Hydrolases: 2391
        Phospholipases: 2589
        Phospholipase D: 472
        glycoprotein phospholipase D: 43

Experts

1.	Deeg, Mark A: 4 articles (10/2010 - 02/2004)
2.	Huang, He: 3 articles (09/2014 - 02/2006)
3.	Bowen, R F: 3 articles (08/2004 - 07/2001)
4.	Deeg, M A: 3 articles (08/2004 - 07/2001)
5.	Naghibalhossaini, Fakhraddin: 2 articles (04/2012 - 03/2006)
6.	Bergström, Jörgen: 2 articles (02/2012 - 01/2012)
7.	Henriksson, Anders E: 2 articles (02/2012 - 01/2012)
8.	Wallinder, Jonas: 2 articles (02/2012 - 01/2012)
9.	Raikwar, Nandita S: 2 articles (10/2010 - 06/2006)
10.	Xiao, Guang-Fen: 2 articles (02/2010 - 06/2005)

Related Diseases

1.	Insulinoma 02/01/1997 - "In this report we examined the regulation of GPI-PLD secretion from beta TC3 cells, a mouse insulinoma cell line. " 10/01/2010 - "Overexpressing GPI-PLD in an insulinoma cell line enhanced glucose-stimulated insulin secretion, suggesting that enhanced insulin secretion in vivo may have contributed to the improved glucose tolerance." 12/01/2001 - "To determine if GPI-PLD is regulated in islet beta cells, we examined the effect of glucose and insulin on GPI-PLD expression in rat islets and murine insulinoma cell lines. "
2.	Neoplasms (Cancer) 01/01/2007 - "Recent studies suggested that the mechanisms of the malignancy and prognosis of certain tumors were correlated with GPI-PLD. " 09/01/2014 - "Nude mice models showed that the tumor growth and tumor weight [(1.87 ± 0.09) g] of the GPI-PLD group were significantly less than those of the blank control group [(2.20 ± 0.17) g] and the negative control group [(2.15 ± 0.09) g]. " 12/01/2007 - "As hematopoietic stem/progenitor cells (HS/PC) homing was similar to tumor invasion and metastasis in some mechanisms, which arose our interests in whether GPI-PLD contribution to the homing of HS/PC. " 04/01/2012 - "While there was a positive relationship between AP release and the levels of GPI-PLD transcript expression, we found no direct correlation between CEA released from cancer cells and the GPI-PLD mRNA expression level. " 04/01/2012 - "All five cancer cell lines analyzed expressed GPI-PLD protein. "
3.	Insulin Resistance 04/01/2008 - "The study's main outcome measures were plasma GPI-PLD levels and insulin sensitivity as estimated by the homeostasis model assessment. " 02/01/2004 - "These results suggest that increased serum GPI-PLD is associated with the insulin resistance." 02/01/2004 - "Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D." 04/01/2008 - "Plasma GPI-PLD may serve as a clinical tool to determine the effect of a low-fat diet on insulin sensitivity." 04/01/2008 - "Plasma glycosylphosphatidylinositol-specific phospholipase D predicts the change in insulin sensitivity in response to a low-fat but not a low-carbohydrate diet in obese women."
4.	Non-alcoholic Fatty Liver Disease 06/01/2006 - "The objective of the study was to determine whether alterations in serum and hepatic levels of GPI-PLD occur in patients with NAFLD. " 06/01/2006 - "Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: a preliminary study." 06/01/2006 - "These results suggest that GPI-PLD may play a role in the pathogenesis of NAFLD and/or its metabolic features and warrants further investigation." 06/01/2006 - "Patients with NAFLD have elevated serum levels and hepatic expression of GPI-PLD, and its overexpression in vitro is associated with increased expression of de novo lipogenesis genes. " 06/01/2006 - "The serum levels of GPI-PLD were significantly higher in patients with nonalcoholic steatohepatitis than in matched controls (119 +/- 24 vs.105 +/- 15 microg/ml, P = 0.047). "
5.	Type 2 Diabetes Mellitus (MODY) 01/01/2016 - "The Clinical Significance of Glycoprotein Phospholipase D Levels in Distinguishing Early Stage Latent Autoimmune Diabetes in Adults and Type 2 Diabetes." 08/01/2004 - "Glycosylphosphatidylinositol-specific phospholipase D immunoreactivity is present in islet amyloid in type 2 diabetes." 01/01/2019 - "Previous human studies suggested the relationship of GPI-PLD to insulin resistance, type 1 and type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD). " 08/01/2004 - "Since GPI-PLD also inhibited islet amyloid polypeptide fibril formation in vitro, it is concluded that GPI-PLD may play a role in islet amyloid formation in type 2 diabetes."

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	glycoprotein phospholipase D
3.	Phospholipase D
4.	Inositol (Myoinositol)
5.	placental alkaline phosphatase
6.	Biomarkers (Surrogate Marker)
7.	Glycoproteins (Glycoprotein)
8.	Nonidet P-40
9.	Messenger RNA (mRNA)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Carbohydrate-Restricted Diet (Low Carbohydrate Diet)
2.	Fat-Restricted Diet (Diet, Fat Restricted)
3.	Hemodilution